3 / 8
Page 15
Notes:
J Neurol Neurorehabil Res 2017 | Volume 2 Issue 3
allied
academies
17
th
International Conference on
4
th
International Conference on
NEUROLOGY AND NEUROSCIENCE
&
MENTAL HEALTH AND PRIMARY CARE
October 16-18, 2017 | Toronto, Canada
P
ET (Positron Emission Tomography) is one of the most
effective methodologies for the functional and molecular
imaging of human brain with high sensitivity and quantitative
measurement. This consists from the coincident matrix
detection technique and the in-vivo positron tracer. In 1976,
the first brain regional glucose consumption mapping in
human had been succeeded with
18
FDG in collaboration among
of Brookhaven National Laboratory, NIH and Pennsylvania
University. These regional glucose consumption mapping had
led to understanding the function of central nerves system
(specially, sensor cortex and mortar cortex). In 1982, the first
neuro-receptor imaging (Dopamine D2) human brain in-vivo
with
11
C-methylspiperon was succeeded in the collaborative
work between Johns Hopkins Medical School and Uppsala
University. This was the starting point of the molecular imaging
by PET. After this, the compounds related to signal transduction
(agonist, antagonist) were labelled with
11
C or
18
F and applied to
determination of synapse activity. Dopaminergic, Serotonergic,
Cholinergic, Histaminergic, GABAergic, Glutamatergic receptors
can be determined by this method. Also positron labelled MAO
inhibitor and ACh-esterase inhibitor are applied to diagnosis
of Parkinson’s disease (PD) and Alzheimer’s diseases (AD).
Recent highlight works in Brain PET research are the imaging of
amyloidal plaque and active tau protein for AD patient.
11
C- and
18
F-labelled thioflavinanalogshavebeendevelopedas amyloidal
plaque marker. Active tau protein image by
18
F-THK compound
(quinoline derivative) is closer related to cell denature than
amyloidal plaque image. Another highlight work is the imaging
of neuro-inflammation that may be important to find tissue
denature at early stages in PD, AD and other neurodegenerative
diseases. For this purpose, TSPO (translocator protein) ligand
(phenoxy phenyl acetamide and oxo purine derivatives) is
labelled with
11
C and
18
F. Development of PET methodology
requires both factors such as the progressing of detection
equipment and the finding of new radiopharmaceuticals which
are suitable for functional imaging and molecular imaging.
Speaker Biography
Tatsuo Ido is a Chair Professor and the Director of Theragnostic Compound R&D
Center, Neuroscience Research Institute, Gachon University (Republic of Korea)
and Emeritus Professor of Tohoku University (Japan). He had completed his PhD of
Pharmaceutical Sciences at Graduate School of Tokyo University (Tokyo, Japan) in 1970.
He has investigated PET radio-pharmaceuticals for near 50 years at National Institute
of Radiological Sciences (Chiba, Japan), Brookhaven National Laboratory (Long Island,
USA) and Tohoku University (Sendai, Japan). In 1976 at BNL, he had succeeded first
synthesis of
18
FDG and applied to human brain functional study. After retired as
Professor of Tohoku University, he had continued his research work as Professor of
High Energy Biomedical Research Center of Fukui University (Fukui, Japan). From 2007
to 2012, he had leaded stable supply of radioisotopes in Japan at Japan Radioisotope
Association as Executive Director. From 2013 until present, he is working continuously
in developing new PET radiopharmaceuticals in Neuroscience research field.
e:
ido@gachon.ac.krTatsuo Ido
Gachon University, Republic of Korea
Radiopharmaceuticals for PET imaging of brain functions